Idec ( BIIB ) recently signed a deal to acquire privately-held biotech company, Stromedix, Inc. With this acquisition, Biogen will gain access to treatments being developed for fibrosis and organ failure. The lead candidate at Stromedix is STX-100,...

Biogen Idec has agreed to acquire five-year-old, privately-held Stromedix Inc for $75 million upfront and up to $487.5 million in milestones. But there is a twist to the buyout, as the research programme at the heart of the startup – which is also...

Inc. and STC Biologics, both of Cambridge, are developing biosimilars, and Quintiles Transnational Corp. , based in North Carolina and with offices in Cambridge, early last year inked a $266 million partnership with South Korea’s Samsung Group to...

Ansys, Inc. (NASDAQ: ANSS), which develops and markets engineering simulation technology, has 34% of total revenue ($660M), from the region (they report Feb. 23rd). And Biogen Idec, Inc. (NASDAQ: BIIB), a biotechnology firm, also generates 34% of their...

Biogen will pay $75 million up front, and up to $487.5 million in milestones for the company, gaining Stromedix's humanized monoclonal antibody, STX-100. There is no approved treatment for idiopathic pulmonary fibrosis, and it has a very high mortality...

Uniendo nuestras fuerzas, prevemos acelerar el desarrollo de STX-100 y de otros prometedores candidatos a fármacos en fase previa. Es un nuevo capítulo para todos nosotros en Stromedix y estamos deseando vivir un futuro brillante como parte de Biogen...